| autoinflammation |
331 |
| autoinflammatory diseases |
331 |
| familial mediterranean fever |
331, 384 |
| arthritis |
339, 447 |
| differences |
339 |
| geographic locations |
339 |
| psoriatic |
339 |
| regional |
339 |
| spondyloarthritis |
339, 368 |
| creatine kinase |
350 |
| il-6 inhibitor |
350 |
| jak inhibitor |
350 |
| multicenter observational study |
350 |
| rheumatoid arthritis |
350, 411, 429 |
| cross-sectional study |
358 |
| gout |
358, 393 |
| health literacy |
358 |
| self-management |
358 |
| biomarkers |
368 |
| chemokine ccl17 |
368 |
| gm-csf |
368 |
| fibromyalgia syndrome |
375 |
| oxidative stress |
375 |
| proprotein convertase subtilisin/kexin type 9 |
375 |
| chronic pain |
384 |
| juvenile fibromyalgia syndrome |
384 |
| juvenile idiopatic arthritis |
384 |
| tiredness |
384 |
| cardiovascular diseases |
393 |
| carotid intima-media thickness |
393 |
| dysfunction |
393 |
| erectile |
393 |
| insulin resistance |
393 |
| antinuclear antibodies |
404 |
| extraglandular involvement |
404 |
| focus score |
404 |
| sjögren's syndrome |
404 |
| systemic manifestations |
404 |
| awareness |
411 |
| knowledge |
411 |
| osteoporosis |
411 |
| axial spondyloarthropathy |
419 |
| biological agents |
419 |
| difficult-to-treat |
419 |
| disease activity |
419 |
| drug-switching |
419 |
| arrhythmia |
429 |
| electrocardiography |
429 |
| musculoskeletal pain |
436 |
| neuropathic pain |
436 |
| post-covid-19 |
436 |
| exercise |
447 |
| patient reported outcome |
447 |
| reliability |
447 |
| validity |
447 |
| knee osteoarthritis |
459 |
| ozone therapy |
459 |
| proinflammatory cytokines |
459 |
| abducens nerve |
479 |
| giant cell arteritis |
479 |
| six nerve palsy |
479 |
| systematic review |
479 |
| anca-associated vasculitis |
488 |
| systemic review |
488 |
| bronchiectasis |
488 |
| prevalence |
488 |
| association |
488 |
